COVID-19 Vaccine Acceptance Among Parents of Children With Multisystem Inflammatory Syndrome in Children.
Journal
The Pediatric infectious disease journal
ISSN: 1532-0987
Titre abrégé: Pediatr Infect Dis J
Pays: United States
ID NLM: 8701858
Informations de publication
Date de publication:
01 Apr 2024
01 Apr 2024
Historique:
medline:
11
3
2024
pubmed:
19
1
2024
entrez:
19
1
2024
Statut:
ppublish
Résumé
Data on COVID-19 vaccine acceptability among parents of children with multisystem inflammatory syndrome (MIS-C) are limited. In this cohort of children with MIS-C, enrolled in the Swissped RECOVERY trial (NCT04826588), comparing intravenous immunoglobulins or methylprednisolone, who, in accordance with Swiss guidelines, were recommended for SARS-CoV-2 vaccination, 65% (73/112) of parents reported being vaccinated against SARS-CoV-2 before the MIS-C, while 70% were vaccinated after the MIS-C episode of their child. None of the children were vaccinated before the occurrence of the MIS-C, and only 9% (5/56) received the COVID-19 vaccine after the MIS-C. The predominant barriers to COVID-19 vaccination were concerns over potential side effects and insufficient support from their doctors. This emphasizes the crucial role of health care providers in promoting COVID-19 vaccination among children.
Identifiants
pubmed: 38241661
doi: 10.1097/INF.0000000000004206
pii: 00006454-202404000-00014
pmc: PMC10919269
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
361-364Investigateurs
Henrik Koehler
(H)
Spyridoula Gysi
(S)
Indra Janz
(I)
Andreas Bieri
(A)
Birgit Donner
(B)
Jürg Hammer
(J)
Ulrich Heininger
(U)
Clemens von Kalckreuth
(C)
Malte Kohns
(M)
Nicole Mettauer
(N)
Alexandra Meyer
(A)
Diana Reppucci
(D)
Chloé Schlaeppi
(C)
Daniel Trachsel
(D)
Nina Vaezipour
(N)
Andreas Woerner
(A)
Andreas Zutter
(A)
Federica Vanoni
(F)
Lisa Kottanattu
(L)
Calogero Mazzara
(C)
Alessia Severi Conti
(A)
Christoph Aebi
(C)
Philipp Agyeman
(P)
Andrea Duppenthaler
(A)
Martin Glöckler
(M)
Sabine Pallivathukal
(S)
Thomas Riedel
(T)
Petra Zimmermann
(P)
Hong-Phuc Cudré-Cung
(HP)
Mladen Pavlovic
(M)
Alice Bordessoule
(A)
Anne-Laure Martin
(AL)
Angelo Polito
(A)
Noemie Wagner
(N)
Marie Rohr
(M)
Arnaud L'Huillier
(A)
Vivianne Amiet
(V)
Thomas Ferry
(T)
David Longchamp
(D)
Julia Natterer
(J)
Rebecca Oppenheim
(R)
Michael Hofer
(M)
Michael Buettcher
(M)
Katharina Wechselberger
(K)
Alex Donas
(A)
Sara Germann
(S)
Michaela Lütolf Erni
(M)
Daniela Kaiser
(D)
Katharina Schwendener Scholl
(K)
Hans Peter Kuen
(H)
Katja Hrup
(K)
Janine Stritt
(J)
Douggl G N Bailey
(DGN)
Tanja Wachinger
(T)
Ingrid Beck
(I)
André Birkenmaier
(A)
Bjarte Rogdo
(B)
Philip Lorenz
(P)
Ivo Iglowstein
(I)
Konstanze Zöhrer
(K)
Martin Flade
(M)
Seraina Prader
(S)
Jana Pachlopnik Schmid
(J)
Michelle Seiler
(M)
Patrick Meyer Sauteur
(P)
Barbara Brotschi
(B)
Kathrin Weber
(K)
Elizabeth Whittaker
(E)
Saul N Faust
(SN)
Informations de copyright
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Zambrano LD, Newhams MM, Olson SM, et al.; Overcoming COVID-19 Investigators. Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA vaccination against multisystem inflammatory syndrome in children among persons aged 12-18 years - United States, July-December 2021. MMWR Morb Mortal Wkly Rep. 2022;71:52–58.
Zambrano LD, Newhams MM, Olson SM, et al.; Overcoming COVID-19 Investigators. BNT162b2 mRNA vaccination against coronavirus disease 2019 is associated with a decreased likelihood of multisystem inflammatory syndrome in children aged 5-18 years-United States, July 2021 - April 2022. Clin Infect Dis. 2023;76:e90–e100.
F.C.o. Switzerland. COVID-19: vaccination recommended and possible for children from the beginning of January. 2021. https://www.admin.ch/gov/en/start/documentation/media-releases.msg-id-86451.html#:~:text=beginning%20of%20January-,COVID%2D19%3A%20vaccination%20recommended%20and%20possible%20for%20children,from%20the%20beginning%20of%20January&text=Bern%2C%2014.12.,aged%20between%20five%20and%20eleven .
C. Centers for Disease. Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States. 2021. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html .
C. Government. COVID-19 vaccine: Canadian Immunization Guide. 2021. https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-26-covid-19-vaccine.html .
Epalza C, Prieto-Tato L, Pino R, et al.; EPICO-AEP Working Group. Safety and acceptance of COVID-19 vaccination after multisystem inflammatory syndrome in children (MIS-C) in Spain. J Pediatric Infect Dis Soc. 2022;11:471–473.
Minoia F, Lucioni F, Heshin-Bekenstein M, et al. Approaches to SARS-CoV-2 and other vaccinations in children with a history of multisystem inflammatory syndrome (MIS-C): an international survey. Front Pediatr. 2022;10:1030083.
Conseil d’Orientation de la Stratégie VaccinaleConseil d’Orientation de la Stratégie Vaccinale du gouvernement français. Vaccination des enfants et adolescents ayant développé un PIMS, Note du 8 février. 2022. https://sante.gouv.fr/IMG/pdf/cosv_-_note_du_8_fevrier_-_vaccination_des_enfants_ayant_developpe_un_pims.pdf .
Welzel T, Atkinson A, Schobi N, et al.; Swissped RECOVERY Trial Group. Methylprednisolone versus intravenous immunoglobulins in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS): an open-label, multicentre, randomised trial. Lancet Child Adolesc Health. 2023;7:238–248.
Welzel T, Schobi N, Andre MC, et al.; Swissped Recovery Trial. Multicenter randomized trial of methylprednisolone vs intravenous immunoglobulins to treat the pediatric inflammatory multisystem syndrome-temporally associated with SARS-CoV-2 (PIMS-TS): protocol of the Swissped RECOVERY Trial. Front Pediatr. 2022;10:905046.
R Foundation for Statistical Computing. R Care Team: a language and environment for statistical computing. Austria; 2020.
Wisniak A, Baysson H, Pullen N, et al.; Specchio-COVID19 study group. COVID-19 vaccination acceptance in the canton of Geneva: a cross-sectional population-based study. Swiss Med Wkly. 2021;151:w30080.
Malik AA, McFadden SM, Elharake J, et al. Determinants of COVID-19 vaccine acceptance in the US. EClinicalMedicine. 2020;26:100495.
Hursh SR, Strickland JC, Schwartz LP, et al. Quantifying the impact of public perceptions on vaccine acceptance using behavioral economics. Front Public Health. 2020;8:608852.
Blanchard-Rohner G, Caprettini B, Rohner D, et al. Impact of COVID-19 and intensive care unit capacity on vaccination support: evidence from a two-leg representative survey in the United Kingdom. J Virus Erad. 2021;7:100044.
Peirolo A, Posfay-Barbe KM, Rohner D, et al. Acceptability of COVID-19 vaccine among hospital employees in the Department of Paediatrics, Gynaecology and Obstetrics in the University Hospitals of Geneva, Switzerland. Front Public Health. 2021;9:781562.
Galanis P, Vraka I, Siskou O, et al. Willingness, refusal and influential factors of parents to vaccinate their children against the COVID-19: a systematic review and meta-analysis. Prev Med. 2022;157:106994.
Rane MS, Robertson MM, Westmoreland DA, et al. Intention to vaccinate children against COVID-19 among vaccinated and unvaccinated US Parents. JAMA Pediatr. 2022;176:201–203.
Mondal P, Sinharoy A. The influence of pediatricians’ recommendation on caregivers’ COVID-19 vaccine acceptance for children: a nationwide cross-sectional survey study from USA. Front Pediatr. 2023;11:1149125.
Shmueli L. Parents’ intention to vaccinate their 5- to 11-year-old children with the COVID-19 vaccine: rates, predictors and the role of incentives. BMC public health. 2023;23:328.
Yousaf AR, Kunkel A, Abrams JY, et al. COVID-19 vaccine reactogenicity and vaccine attitudes among children and parents/guardians after multisystem inflammatory syndrome in children or COVID-19 hospitalization: September 2021-May 2022. Pediatr Infect Dis J. 2023;42:252–259.